Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study.
Fiche publication
Date publication
avril 2024
Journal
Cardiovascular and interventional radiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GANGI Afshin, Pr LANG Hervé, Pr LIPSKER Dan, Pr MEYER Nicolas
Tous les auteurs :
Braud A, Auloge P, Meyer N, Bouvrais C, Gharbi M, Lang H, Gangi A, Lipsker D
Lien Pubmed
Résumé
Complete lymph node dissection is the recommended treatment for clinically detectable lymph nodes in stage III melanoma. This surgery is associated with substantial morbidity. We hypothesize that combining percutaneous imaging-guided cryoablation of locoregional lymph nodes metastases with neoadjuvant in situ and systemic immunotherapy could allow disease control and evaluate the feasibility of this combination in this proof-of-concept study.
Mots clés
Immunotherapy, Melanoma, Neoadjuvant, Percutaneous cryoablation, Stage III
Référence
Cardiovasc Intervent Radiol. 2024 04 3;: